Positive data from Larimar Therapeutics, Inc.'s phase 2 study on nomlabofusp for Friedreich's Ataxia suggests growth in the ...

Medically reviewed by Lindsay Cook, PharmD Vicodin (hydrocodone-acetaminophen) and Percocet (oxycodone-acetaminophen) are ...

Following successful trials demonstrating marked improvement in blood alcohol reduction, Safety Shot's clinically-backed, patented formula is now available in convenient on-the-go stick packs.

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

The Advisory Committee on Immunization Practices (ACIP) recommendations have been updated for the meningococcal serogroup B MenB-4C vaccine (Bexsero).

One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when accompanied by psychotherapy, a new study suggests. A second new study ...

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple ...

Hanx Biopharmaceuticals, CO. Ltd, today announced the first patient dosing in Australia on Dec 30, 2024 for Phase 1 clinical ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who ...